贝伐单抗联合化疗治疗晚期结直肠癌22例临床观察

目的观察贝伐单抗与化疗药物联合治疗晚期结直肠癌的近期疗效和毒副作用。方法在22例经组织或细胞病理学证实的晚期结直肠癌患者中，应用贝伐单抗与化疗药物联合治疗。贝伐单抗的剂量采用美国综合癌症网（NCCN）指南推荐的5mg／kg，每2周重复；或7．5mg／kg，每3周重复。每2个周期后评价疗效并记录毒副作用。结果22例患者中有6例（27．3％）部分缓解，12例（54．5％）稳定，4例（18．2％）进展，客观有效率（ORR）为27．3％，疾病控制率（DCR）为81．8％。毒副作用主要为高血压4例、尿隐血阳性1例、血尿1例，均为1～2级；另出现1例蛋白尿3级，予对症治疗后好转。另外，有3例患者出现III～IV度粒细胞减少，4例出现迟发性腹泻。结论贝伐单抗联合化疗治疗晚期结直肠癌的疗效确切、疾病控制率高、不良反应无明显加重，患者耐受性好。

Clinical study on bevacizumab combined with chemotherapy for treatment of advanced colorectal cancer

Objective To evaluate the efficacy and adverse effects of bevacizumab combined with chemotherapy in treatment of patients with advanced colorectal cancer. Methods Twenty - two patients with advanced colorectal cancer were treated with bevacizumab combined with chemotherapy. Bevacizumab was given with 5mg/kg every two weeks, or 7.5 mg/kg every 3 weeks. Efficacy of treatment was evaluated every two cycles of treatment, and adverse effects were reccorded at the same time. Results Six of twenty - two patients had partial response and twelve pa- tients got stable disease and four patients got progressive disease. The response rate was 27.3% and control rate of the disease was 81.8%. The adverse events related to bevacizumab were hypertension in 4 patients, positive occult blood in urine in 1 patient, hematuria in 1 patient, and all adverse effects were in grade 1 or 2 except 1 patient with grade 3 proteinuria. There were 3 patients with grade 3 or 4 myelosuppression, and 4 pa- tients had tardive diarrhea. Conclusion Bevacizumab combined with chemotherapy is effective in treatment of patients with advanced colorectal cancer with mild adverse effects. It can be used as first - line, second - line or later therapy for treatment of patients with metastatic colorectal